
Sign up to save your podcasts
Or


Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By Andreessen Horowitz, a16z Bio + Health4.5
149149 ratings
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

1,297 Listeners

538 Listeners

2,002 Listeners

1,109 Listeners

2,346 Listeners

3,987 Listeners

233 Listeners

338 Listeners

104 Listeners

10,240 Listeners

554 Listeners

25 Listeners

173 Listeners

300 Listeners

60 Listeners

477 Listeners

34 Listeners

40 Listeners